PURE Bioscience, Inc.
PURE
$0.05
$0.001.17%
OTC PK
| 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 12.18% | -8.56% | -9.48% | -15.55% | 4.58% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.18% | -8.56% | -9.48% | -15.55% | 4.58% |
| Cost of Revenue | 10.85% | -10.19% | -15.64% | -21.60% | -10.49% |
| Gross Profit | 13.11% | -7.35% | -4.49% | -10.47% | 18.64% |
| SG&A Expenses | -18.14% | -17.65% | -12.21% | -10.00% | -7.46% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -12.17% | -15.21% | -12.15% | -11.62% | -7.47% |
| Operating Income | 27.44% | 19.56% | 13.84% | 9.13% | 13.70% |
| Income Before Tax | 28.39% | 22.15% | 14.95% | 10.78% | 15.43% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 28.39% | 22.15% | 14.95% | 10.78% | 15.43% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 28.39% | 22.15% | 14.95% | 10.78% | 15.43% |
| EBIT | 27.44% | 19.56% | 13.84% | 9.13% | 13.70% |
| EBITDA | 25.13% | 18.77% | 13.99% | 10.22% | 15.04% |
| EPS Basic | 28.57% | 22.39% | 15.24% | 10.81% | 15.45% |
| Normalized Basic EPS | 27.17% | 16.76% | 8.60% | 4.23% | 9.80% |
| EPS Diluted | 28.57% | 22.39% | 15.24% | 10.81% | 15.45% |
| Normalized Diluted EPS | 27.17% | 16.76% | 8.60% | 4.23% | 9.80% |
| Average Basic Shares Outstanding | 0.01% | 0.07% | 0.18% | 0.29% | 0.41% |
| Average Diluted Shares Outstanding | 0.01% | 0.07% | 0.18% | 0.29% | 0.41% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |